Amarin (NASDAQ:AMRN) had its price objective hoisted by analysts at Jefferies Financial Group from $7.00 to $15.00 in a research report issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective indicates a potential upside of 11.52% from the company’s current price.

Several other equities analysts have also recently issued reports on the stock. ValuEngine upgraded shares of Amarin from a “buy” rating to a “strong-buy” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price (up from $10.00) on shares of Amarin in a research note on Tuesday. Citigroup boosted their target price on shares of Amarin from $5.00 to $17.00 and gave the company a “reduce” rating in a research note on Tuesday. Cantor Fitzgerald set a $10.00 target price on shares of Amarin and gave the company a “buy” rating in a research note on Tuesday, June 12th. Finally, BidaskClub upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday, May 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $13.20.

AMRN stock opened at $13.45 on Tuesday. The company has a debt-to-equity ratio of -1.25, a quick ratio of 1.13 and a current ratio of 1.43. Amarin has a 12 month low of $2.35 and a 12 month high of $14.64.

Amarin (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.03). The firm had revenue of $52.64 million for the quarter, compared to analyst estimates of $54.88 million. Amarin’s revenue was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.04) earnings per share. research analysts predict that Amarin will post -0.38 earnings per share for the current fiscal year.

In other Amarin news, Director Joseph S. Zakrzewski sold 500,000 shares of the company’s stock in a transaction on Monday, September 24th. The shares were sold at an average price of $10.60, for a total transaction of $5,300,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steven B. Ketchum sold 879,241 shares of the company’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $11.10, for a total transaction of $9,759,575.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,635,889 shares of company stock valued at $28,105,096. Company insiders own 4.08% of the company’s stock.

Large investors have recently bought and sold shares of the business. Private Advisor Group LLC raised its position in Amarin by 81.8% during the first quarter. Private Advisor Group LLC now owns 64,293 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 28,929 shares during the period. DRW Securities LLC raised its position in Amarin by 45.1% during the first quarter. DRW Securities LLC now owns 80,400 shares of the biopharmaceutical company’s stock worth $242,000 after acquiring an additional 25,000 shares during the period. Claraphi Advisory Network LLC raised its position in Amarin by 637.3% during the first quarter. Claraphi Advisory Network LLC now owns 85,309 shares of the biopharmaceutical company’s stock worth $257,000 after acquiring an additional 73,738 shares during the period. Northern Trust Corp raised its position in Amarin by 20.9% during the second quarter. Northern Trust Corp now owns 113,327 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 19,590 shares during the period. Finally, TD Asset Management Inc. raised its position in Amarin by 54.4% during the second quarter. TD Asset Management Inc. now owns 134,207 shares of the biopharmaceutical company’s stock worth $415,000 after acquiring an additional 47,300 shares during the period. Institutional investors own 38.27% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Recommended Story: Dividend Stocks – Are They Right For You?

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.